Oligodendroglioma

P1/2, N=30, Recruiting, Aveta Biomics, Inc. | Trial completion date: Jan 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

Compared to supratentorial tumors, non-R132H IDH1 mutations are significantly more frequent in infratentorial tumors. IDH2-mutant gliomas almost exclusively occur in adults and in supratentorial locations, with a significantly higher proportion in oligodendrogliomas than astrocytoma.

P1, N=24, Not yet recruiting, Megan Mantica

The detection of 1p19q co-deletion in other tumors and its peculiar relationship with MGMT methylation made us think of the complexity of tumor biology and how both genetic and epigenetic factors interplay to influence tumor behavior and response to therapy.

P3, N=57, Active, not recruiting, Servier | Trial primary completion date: Oct 2025 --> May 2026

P1, N=60, Completed, Case Comprehensive Cancer Center | Active, not recruiting --> Completed

Oligo Cdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single cell sequencing identified a bias towards oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model. Oligo Cdkn2a tumors represent the first mouse model system to recapitulate the genetic, histological and transcriptional features of human IDH-mutant 1p/19q-codeleted oligodendrogliomas, offering a platform to further dissect tumor biology and test new therapeutic strategies.

Second, increased mesenchymal-like-state abundance occurred independently of acquired genetic alterations and instead coincided with elevated macrophage expression. Overall, our findings provide an integrative model that traces the cell intrinsic and extrinsic factors that shape cellular states during IDH-mutant glioma disease progression.

P1, N=3, Terminated, University of Rochester | N=30 --> 3 | Active, not recruiting --> Terminated; lack of enrollment

This study confirms that, despite its name, PLNTY is not limited to pediatric patients. Findings underscore the highly epileptogenic nature of PLNTY and its recognizable electroclinical features, potentially related to its distinctive neuropathology. Most PLNTYs show mitogen-activated protein kinase (MAPK) pathway activating alterations, demonstrated by BRAFV600E mutation and FGFR3 fusion.

P1, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Feb 2030 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027

Thus, DNTs with high confidence scores are relatively homogenous but DNTs with low methylation confidence scores are heterogenous, highlighting the importance of integrated molecular profiling. Our findings also suggest that the myxoid glioneuronal tumor methylation class may require further classification of underlying drivers.